5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5 Dapagliflozin Intermediate Factory

Name: 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane Synonyms: 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene  CAS: 461432-23-5 Purity: ≥99.0% (HPLC) Appearance: White to Pael Yellow Crystalline Powder Intermediate of Dapagliflozin (CAS: 461432-26-8) in the treatment of type II diabetes High Quality, Commercial Production Inquiry: alvin@ruifuchem.com

Products Details

Chemical Properties:

Package: Bottle, Aluminium foil bag, Cardboard Drum, 25kg/Drum, or according to customer's requirement. Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture.Manufacturer Supply, High Purity, Commercial Production Dapagliflozin (CAS: 461432-26-8) Related Intermediates: 5-Bromo-2-Chlorobenzoic Acid CAS 21739-92-4 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane CAS 461432-23-5 2,3,4,6-Tetrakis-O-Trimethylsilyl-D-Gluconolactone CAS 32384-65-9
Item Specifications
Appearance White to Pael Yellow Crystalline Powder
Purity / Analysis Method ≥99.0% (HPLC)
Water (K.F) ≤0.50%
Total Impurities ≤1.0%
Test Standard Enterprise Standard
Usage Intermediate of Dapagliflozin (CAS: 461432-26-8), type II diabetes

Description:

Specifications:

Package & Storage:

Chemical Name 5-Bromo-2-Chloro-4'-Ethoxydiphenylmethane
Synonyms 4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene; 4-(5-Brom-2-Chlorbenzyl)phenyl-Ethylether; Dapagliflozin Bromo Impurity
CAS Number 461432-23-5
CAT Number RF-PI447
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C15H14BrClO
Molecular Weight 325.63
Melting Point 41.0 to 43.0℃
Brand Ruifu Chemical

Advantages:

FAQ:

Application:

4-Bromo-1-Chloro-2-(4-Ethoxybenzyl)benzene (CAS: 461432-23-5) is used as a intermediate in the synthesis of Dapagliflozin (CAS: 461432-26-8). Dapagliflozin is a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. Dapagliflozin is a new antidiabetic drug jointly developed by Bristol-Myers Squibb and AstraZeneca, being approved by the European Medicines Agency (EMA) on November 12, 2012. On January 8, 2014, the US Food and Drug Administration (FDA) have approved it for being used in the treatment of type II diabetes. 

Contact us

Please feel free to give your inquiry in the form below We will reply you in 24 hours